Effects of fluticasone propionate in COPD patients
نویسندگان
چکیده
منابع مشابه
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone ...
متن کاملScientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
Inhaled corticosteroids (ICSs) treatment combined with long-acting β2-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate than for budesonide. We have examined systematic reviews assessing the risk of pneumonia associate...
متن کاملSalmeterol combined with fluticasone propionate improved COPD in patients during stable stage.
PURPOSE To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 μg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. METHODS Sixty patients with moderate to severe COPD were randomly divided into trial and control groups (N=30 each). In the trial group, patients inhaled Salmeterol with Fl...
متن کاملFluticasone propionate reduces bacterial airway epithelial invasion.
Fluticasone propionate reduces the frequency and severity of the episodes of exacerbation of chronic obstructive pulmonary disease (COPD). Streptococcus pneumoniae and Haemophilus influenzae are frequently isolated in these episodes. Both express phosphorylcholine, an epitope that mediates their interaction with airway epithelial cells via the platelet-activating factor receptor (PAFR). The pre...
متن کاملNon-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients
BACKGROUND Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2002